Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018091637) PROBIOTIC YEASTS AS NOVEL VACCINATION VECTORS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/091637 International Application No.: PCT/EP2017/079557
Publication Date: 24.05.2018 International Filing Date: 17.11.2017
IPC:
C07K 14/16 (2006.01) ,A61K 38/16 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005
from viruses
08
RNA viruses
15
Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
155
Lentiviridae, e.g. human immunodeficiency virus (HIV), visna-maedi virus, equine infectious anaemia virus
16
HIV-1
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Applicants:
FONDAZIONE RI.MED [IT/IT]; Via Bandiera 11 90133 Palermo, IT
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US/US]; 1st Floor Gardner Steel Conference Center 170 Thackeray Street Pittsburgh, PA 15260, US
Inventors:
DOURADINHA MATEUS, Bruno Goncalo; IT
Agent:
TRILLAT, Anne-Cécile; IT
CAPASSO, Olga; IT
TURRI, Elisa; IT
Priority Data:
10201600011655417.11.2016IT
Title (EN) PROBIOTIC YEASTS AS NOVEL VACCINATION VECTORS
(FR) LEVURES PROBIOTIQUES EN TANT QUE NOUVEAUX VECTEURS DE VACCINATION
Abstract:
(EN) The present invention refers to an immunotherapeutic composition comprising a probiotic yeast vehicle and a fusion protein or a protein comprising at least one HIV antigen and uses thereof. In particular the composition is for the treatment of human immunodeficiency virus (HIV) infection or in the treatment of at least one symptom resulting from HIV infection. The present invention also relates to a method to prepare said immunotherapeutic composition.
(FR) La présente invention concerne une composition immunothérapeutique comprenant un véhicule de levure probiotique et une protéine de fusion ou une protéine comprenant au moins un antigène du VIH, ainsi que ses utilisations. En particulier, la composition est destinée au traitement d'une infection par le virus de l'immunodéficience humaine (VIH) ou dans le traitement d'au moins un symptôme résultant de l'infection par le VIH. La présente invention concerne également une méthode de préparation de ladite composition immunothérapeutique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)